Skip to main content

Drug Interactions between Commit and varenicline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nicotine varenicline

Applies to: Commit (nicotine) and varenicline

MONITOR: Coadministration of varenicline and nicotine replacement therapy has been associated with increased adverse effects. In one study, a higher incidence of nausea, headache, vomiting, dizziness, dyspepsia, and fatigue was observed for the combination compared to transdermal nicotine replacement therapy alone. Eight of the 22 subjects (36%) treated with the combination prematurely discontinued treatment due to adverse events, compared to 1 of 17 (6%) of subjects treated with nicotine replacement therapy and placebo. Varenicline (1 mg orally twice a day) did not affect the pharmacokinetics of nicotine (21 mg/day transdermally) when coadministered for up to 12 days.

MANAGEMENT: The safety and efficacy of varenicline in combination with other smoking cessation therapies have not been established. Tolerability may be reduced if varenicline is coadministered with nicotine replacement therapy.

References (1)
  1. (2006) "Product Information. Chantix (varenicline)." Pfizer U.S. Pharmaceuticals Group

Drug and food interactions

Moderate

varenicline food

Applies to: varenicline

GENERALLY AVOID: Varenicline may enhance the effects of alcohol as well as alter the way an individual reacts to alcohol. During postmarketing use, some patients have reported experiencing increased intoxicating effects of alcohol while taking varenicline. In addition, some reported cases of neuropsychiatric events, including unusual and sometimes aggressive behavior directed toward oneself or others, may have been worsened by concomitant use of alcohol. These events were often accompanied by amnesia.

MANAGEMENT: Patients should be advised to limit their consumption of alcohol until they know whether varenicline affects their tolerance for alcohol, and to exercise caution driving or operating machinery until they know how quitting smoking and/or varenicline may affect them. Patients should immediately stop taking varenicline and contact their physician if they develop agitation, hostility, aggressive behavior, depressed mood, or changes in behavior or thinking that are not typical for them, or if they develop suicidal ideation or behavior.

References (2)
  1. (2006) "Product Information. Chantix (varenicline)." Pfizer U.S. Pharmaceuticals Group
  2. FDA. U.S. Food and Drug Administration (2015) Drug Safety Communications: FDA updates label for stop smoking drug Chantix (varenicline) to include potential alcohol interaction, rare risk of seizures, and studies of side effects on mood, behavior, and thinking. Safety announcement. http://www.fda.go
Minor

nicotine food

Applies to: Commit (nicotine)

One study (n=12) has reported that there was a significant interactive effect of caffeine and nicotine on subjective arousal such that nicotine decreased arousal only in the presence of caffeine. The exact mechanism of this interaction has not been specified. Further research is needed to examine the subjective and physiological interactions between caffeine and nicotine.

References (1)
  1. Rose JE, Behm FM (1991) "Psychophysiological interactions between caffeine and nicotine." Pharmacol Biochem Behav, 38, p. 333-7

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer